Watch MCRB. Know when insiders buy.
One email the day a filing lands. Free.
MCRB
Seres Therapeutics, Inc.
1.96
+0.13 +7.10%
USD · close Nov 3
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
58
WATCH · shorts 58
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $19.5MP/E —DIV YIELD —FCF YIELD -263.26%REV TTM $1.9MNET INCOME −$22.5M −126.1%NET DEBT $94.4M52W 1.77 – 28.63SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $736K | — | — | −$21.3M | $4.6M | — | 0.47 | −$22.4M | $0 | −$22.4M | Aug 5 |
| Q1 2026 · Mar 31 | $358K | — | — | −$20.9M | −$19.9M | −160.9% | -2.08 | −$16.4M | $0 | −$16.4M | Aug 5 |
| Q4 2025 · Dec 31derived | $438K | — | — | −$19.4M | −$15.3M | — | -1.76 | −$14.7M | $29K | −$14.7M | Mar 12 |
| Q3 2025 · Sep 30 | $351K | — | — | −$22.5M | $8.2M | −90.8% | 0.94 | $2.2M | $8K | $2.2M | Nov 5 |
| Q2 2025 · Jun 30 | $0 | — | — | −$24.9M | −$19.9M | — | -2.27 | −$13.3M | $181K | −$13.5M | Aug 5 |
| Q1 2025 · Mar 31 | $0 | — | — | −$27.2M | $32.7M | — | 3.75 | $26.9M | $34K | $26.9M | Aug 5 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$28.8M | −$15.6M | — | -2.10 | −$38.9M | $90K | −$39M | Mar 12 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$29.2M | $88.8M | — | 11.63 | −$34.7M | $129K | −$34.8M | Nov 5 |
| Q2 2024 · Jun 30 | $0 | — | — | −$28.9M | −$32.9M | — | -4.34 | −$39.8M | $99K | −$39.9M | Nov 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$34.4M | −$40.1M | — | -5.49 | −$35.2M | $62K | −$35.3M | Nov 5 |
| Q4 2023 · Dec 31derived | −$126.3M | — | — | −$37M | −$41.2M | — | -17.20 | −$47.5M | $877K | −$48.4M | Mar 12 |
| Q3 2023 · Sep 30 | $310K | — | — | −$44.6M | −$47.9M | — | -0.37 | −$59.3M | $1.8M | −$61.1M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $789K | — | −$94M | $5.7M | 721.9% | 0.64 | $1.1M | $252K | $865K | — | — |
| FY2024 · to Dec 31 | $0 | — | −$121.3M | $136K | — | 0.00 | −$148.6M | $380K | −$149M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$195.1M | −$113.7M | — | -17.77 | −$117.4M | $8M | −$125.3M | — | — |
| FY2022 · to Dec 31 | $7.1M | — | −$179.9M | −$250.2M | -3509.5% | -2.31 | −$228.8M | $9.8M | −$238.6M | — | — |
| FY2021 · to Dec 31 | $144.9M | — | −$64.5M | −$65.6M | -45.2% | -0.72 | $6.7M | $9.6M | −$2.9M | — | — |
| FY2020 · to Dec 31 | $33.2M | — | −$88.1M | −$89.1M | -268.3% | -1.12 | −$93.6M | $591K | −$94.2M | — | — |
Every number comes from Seres Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.